AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III clinical study titled A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05). The study aims to evaluate the efficacy and safety of Dato-DXd, with or without durvalumab, against standard chemotherapy options combined with pembrolizumab in patients with advanced triple-negative breast cancer.
The interventions being tested include the experimental drugs Dato-DXd and durvalumab, which are intended to improve progression-free survival and overall survival in patients. These drugs are compared to standard chemotherapy drugs like paclitaxel, nab-paclitaxel, gemcitabine, and carboplatin, all used with pembrolizumab.
The study is designed as a randomized, open-label, parallel assignment with no masking. The primary purpose is treatment, focusing on comparing the new drug combinations against existing chemotherapy options to determine superior efficacy.
The study began on November 23, 2023, and is currently recruiting participants. The primary completion date is yet to be determined, but the last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical update could potentially influence AstraZeneca’s stock performance positively if the results show significant improvement in treatment outcomes. Investors should watch for further developments, especially considering the competitive landscape of cancer therapeutics.
The study is ongoing, and further details are available on the ClinicalTrials portal.